[Surveys of the epidemiological team of the French Rheumatology Society (RESFR) on the prescription of D-penicillamine in the treatment of rheumatoid polyarthritis].
Two surveys carried out by the Epidemiology Team of the French Rheumatology Society (RESFR) were used to assess the treatment of rheumatoid arthritis (RA) by means of D-penicillamine (DP). In the initial survey, which is described in this article, 119 rheumatologists throughout France were asked to give their opinion as to the place of DP: they use this drug in cases of severe RA, usually after gold salts and synthetic antimalarials have proved ineffective. The dosage is generally 600 mg per day, with a maximum dosage of 900 mg per day. The rheumatologists consider DP an effective treatment with good or fair clinical safety. The most frequent adverse reactions are proteinuria and skin eruptions.
D000328:Adult; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D004363:Drug Utilization; D005260:Female; D005602:France; D006801:Humans; D008297:Male; D008875:Middle Aged; D010396:Penicillamine / Q000008:administration & dosage / Q000627:therapeutic use*; D012219:Rheumatology; D012955:Societies, Medical; D011795:Surveys and Questionnaires
D010396:Penicillamine
Enquêtes du réseau épidémiologique de la Société Française de Rhumatologie (RESFR) sur la prescription de la D-pénicillamine dans le traitement de la polyarthrite rhumatoïde.